8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Feb 26, 2026·SEC
Kymera Therapeutics, Inc.(KYMR)Earnings, Financials & Key Ratios
KYMR•NASDAQ
$82.71
$6.75B mkt cap·Price updated May 6, 2026
AboutKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$39M-16.7%
- EBITDA-$341M-34.1%
- Net Income-$311M-39.1%
- EPS (Diluted)-3.69-23.8%
- Gross Margin100%
- EBITDA Margin-870.12%-61.1%
- Operating Margin-891.33%-60.4%
- Net Margin-794.39%-67.0%
- ROE-25.79%+29.1%
- ROIC-24.86%+25.7%
- Debt/Equity0.05-50.4%
- Interest Coverage-1250.50-39.2%
KYMR Key Insights
Kymera Therapeutics, Inc. (KYMR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 46.9% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 12.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KYMR Price & Volume
Kymera Therapeutics, Inc. (KYMR) stock price & volume — 10-year historical chart
Loading chart...
KYMR Growth Metrics
Kymera Therapeutics, Inc. (KYMR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years2.87%
3 Years-5.75%
TTM-12.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.48%
Return on Capital
10 Years-36.78%
5 Years-30.08%
3 Years-32.32%
Last Year-27.19%
KYMR Recent Earnings
Kymera Therapeutics, Inc. (KYMR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 30, 2026EPS
$0.71
Est $0.89
+20.2%
Revenue
$34M
Est $8M
+315.7%
Q1 2026
Feb 26, 2026EPS
$0.97
Est $0.78
-23.8%
Revenue
$3M
Est $15M
-80.9%
Q4 2025
Nov 4, 2025EPS
$0.90
Est $0.71
-26.8%
Revenue
$3M
Est $14M
-80.9%
Q3 2025
Aug 11, 2025EPS
$0.95
Est $0.83
-14.5%
Revenue
$11M
Est $17M
-33.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.71vs $0.89+20.2% | $34Mvs $8M+315.7% |
| Q1 2026 | Feb 26, 2026 | $0.97vs $0.78-23.8% | $3Mvs $15M-80.9% |
| Q4 2025 | Nov 4, 2025 | $0.90vs $0.71-26.8% | $3Mvs $14M-80.9% |
| Q3 2025 | Aug 11, 2025 | $0.95vs $0.83-14.5% | $11Mvs $17M-33.0% |
Based on last 12 quarters of dataView full earnings history →
KYMR Peer Comparison
Kymera Therapeutics, Inc. (KYMR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 VKTX | 3.63B | 31.31 | -9.82 | -71.31% | 0.00 | |||
 BEAM | 2.97B | 28.90 | -35.68 | 120.01% | -57.24% | -7.31% | 0.24 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 ARQT | 2.89B | 23.42 | -180.15 | 91.34% | -4.29% | -8.52% | 0.03 | |
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PTGX | 6.21B | 99.28 | -48.43 | -100% | -21.17% | 0.93% | 0.02 |
Compare KYMR vs Peers
Kymera Therapeutics, Inc. (KYMR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KYMR Income Statement
Kymera Therapeutics, Inc. (KYMR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M | 51.47M |
| Revenue Growth % | - | - | 1059.99% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | -12.6% |
| Cost of Goods Sold | 205K | 825K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 28.12% | - | - | - | - | - | - | - |
| Gross Profit | -205K▲ 0% | 2.11M▲ 1128.8% | 34.03M▲ 1513.8% | 72.83M▲ 114.0% | 46.83M▼ 35.7% | 78.59M▲ 67.8% | 47.07M▼ 40.1% | 39.2M▼ 16.7% | 17.1M▲ 0% |
| Gross Margin % | - | 71.88% | 100% | 100% | 100% | 100% | 100% | 100% | 33.23% |
| Gross Profit Growth % | - | 1128.78% | 1513.75% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | - |
| Operating Expenses | 21.45M | 45.14M | 80.34M | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M | 410.59M |
| OpEx % of Revenue | - | 1538.48% | 236.05% | 238.03% | 444.37% | 310.62% | 655.82% | 991.33% | - |
| Selling, General & Admin | 3.77M | 7.98M | 18.23M | 36.34M | 43.83M | 55.04M | 63.53M | 68.2M | 72.29M |
| SG&A % of Revenue | - | 272.02% | 53.57% | 49.9% | 93.61% | 70.03% | 134.97% | 173.98% | - |
| Research & Development | 17.68M | 37.16M | 62.1M | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M | 334.51M |
| R&D % of Revenue | - | 1266.46% | 182.48% | 188.13% | 350.76% | 240.59% | 510.38% | 807.65% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 4.92M | 3.8M | -1000K |
| Operating Income | -21.45M▲ 0% | -42.2M▼ 96.8% | -46.3M▼ 9.7% | -100.53M▼ 117.1% | -161.26M▼ 60.4% | -165.53M▼ 2.7% | -261.63M▼ 58.1% | -349.4M▼ 33.5% | -359.13M▲ 0% |
| Operating Margin % | - | -1438.48% | -136.05% | -138.03% | -344.37% | -210.62% | -555.82% | -891.33% | -697.81% |
| Operating Income Growth % | - | -96.75% | -9.71% | -117.11% | -60.41% | -2.65% | -58.06% | -33.54% | - |
| EBITDA | -21.25M | -41.38M | -44.54M | -98.13M | -158.28M | -161.97M | -254.26M | -341.09M | -352.16M |
| EBITDA Margin % | - | -1410.36% | -130.87% | -134.74% | -338.02% | -206.08% | -540.16% | -870.12% | -684.28% |
| EBITDA Growth % | - | -94.77% | -7.64% | -120.32% | -61.29% | -2.33% | -56.99% | -34.15% | -30.3% |
| D&A (Non-Cash Add-back) | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | 6.96M |
| EBIT | -21.45M | -41.2M | -45.48M | -100.04M | -154.63M | -146.77M | -223.61M | -311.37M | -245.87M |
| Net Interest Income | 0 | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M | 37.78M | 28.93M |
| Interest Income | 0 | 1M | 826K | 488K | 6.62M | 18.76M | 38.03M | 38.03M | 29.11M |
| Interest Expense | 16K | 46K | 115K | 175K | 176K | 196K | 249K | 249K | 116K |
| Other Income/Expense | -16K | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M | 37.78M | 43.85M |
| Pretax Income | -21.47M▲ 0% | -41.25M▼ 92.1% | -45.59M▼ 10.5% | -100.22M▼ 119.8% | -154.81M▼ 54.5% | -146.96M▲ 5.1% | -223.86M▼ 52.3% | -311.62M▼ 39.2% | -315.28M▲ 0% |
| Pretax Margin % | - | -1405.79% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.96% | -612.6% |
| Income Tax | 43.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.47M▲ 0% | -41.29M▼ 92.4% | -45.59M▼ 10.4% | -100.22M▼ 119.8% | -154.81M▼ 54.5% | -146.96M▲ 5.1% | -223.86M▼ 52.3% | -311.4M▼ 39.1% | -315.05M▲ 0% |
| Net Margin % | - | -1407.36% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.39% | -612.17% |
| Net Income Growth % | - | -92.35% | -10.42% | -119.81% | -54.47% | 5.07% | -52.32% | -39.11% | -30.79% |
| Net Income (Continuing) | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.62M | -315.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48▲ 0% | -0.93▼ 93.8% | -0.99▼ 6.5% | -2.09▼ 111.1% | -2.87▼ 37.3% | -2.52▲ 12.2% | -2.98▼ 18.3% | -3.69▼ 23.8% | -3.23▲ 0% |
| EPS Growth % | - | -93.75% | -6.45% | -111.11% | -37.32% | 12.2% | -18.25% | -23.83% | -15.48% |
| EPS (Basic) | -0.48 | -0.93 | -0.99 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | - |
| Diluted Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M | 97.53M |
| Basic Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M | 97.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KYMR Balance Sheet
Kymera Therapeutics, Inc. (KYMR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 41.79M | 92.84M | 302.34M | 451.27M | 419.42M | 405.32M | 510.27M | 871.21M | 677.43M |
| Cash & Short-Term Investments | 41.26M | 91.96M | 296.2M | 442.42M | 407.17M | 374.88M | 488.74M | 848.28M | 650.93M |
| Cash Only | 41.26M | 76.02M | 31M | 47.98M | 68.39M | 109.97M | 120.26M | 357.01M | 144.09M |
| Short-Term Investments | 0 | 15.94M | 265.2M | 394.44M | 338.77M | 264.92M | 368.49M | 491.26M | 506.84M |
| Accounts Receivable | 148K | 0 | 1.43M | 135K | 2.54M | 18.76M | 947K | 0 | 0 |
| Days Sales Outstanding | - | - | 15.37 | 0.68 | 19.78 | 87.14 | 7.34 | - | 70.92 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 9.71M | 11.67M | 20.58M | 22.94M | 26.5M |
| Total Non-Current Assets | 2.44M | 23.86M | 184.84M | 154.63M | 183.72M | 170.44M | 467.77M | 871.6M | 991.58M |
| Property, Plant & Equipment | 2.24M | 22.08M | 20.69M | 21.31M | 22.24M | 101.08M | 97.86M | 85.53M | 83.35M |
| Fixed Asset Turnover | - | 0.13x | 1.65x | 3.42x | 2.11x | 0.78x | 0.48x | 0.46x | 0.59x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 199K | 0 | 162.53M | 125.19M | 152.33M | 61.43M | 362.16M | 776.96M | 1.56B |
| Other Non-Current Assets | 0 | 1.77M | 1.62M | 8.14M | 9.15M | 7.93M | 7.74M | 9.11M | 928.85M |
| Total Assets | 44.23M▲ 0% | 116.7M▲ 163.8% | 487.18M▲ 317.5% | 605.9M▲ 24.4% | 603.13M▼ 0.5% | 575.76M▼ 4.5% | 978.03M▲ 69.9% | 1.74B▲ 78.2% | 1.67B▲ 0% |
| Asset Turnover | - | 0.03x | 0.07x | 0.12x | 0.08x | 0.14x | 0.05x | 0.02x | 0.04x |
| Asset Growth % | - | 163.85% | 317.45% | 24.37% | -0.46% | -4.54% | 69.87% | 78.2% | 203.37% |
| Total Current Liabilities | 4.69M | 34.57M | 110.62M | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M | 62.64M |
| Accounts Payable | 2.06M | 3.28M | 4.37M | 4M | 4.33M | 7.08M | 5.99M | 4.01M | 12.84M |
| Days Payables Outstanding | 3.66K | 1.45K | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.76M | 13.73M |
| Deferred Revenue (Current) | 2.32M | 23.35M | 92.55M | 61.74M | 35.26M | 37.88M | 13.58M | 22.93M | 86.2M |
| Other Current Liabilities | 1.31M | 0 | 106K | 228K | 303K | 23.16M | 35.09M | 24.2M | 36.07M |
| Current Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x | 10.47x | 10.47x |
| Quick Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x | 10.47x | 10.47x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | 70.92 |
| Total Non-Current Liabilities | 73.98M | 156.54M | 92.67M | 53.73M | 41.64M | 95.1M | 74.65M | 79.94M | 66.74M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.74M |
| Capital Lease Obligations | 393K | 17.82M | 14.73M | 14.36M | 13.39M | 78.33M | 74.65M | 68.5M | 210.8M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 73.59M | 109.08M | 100K | 66K | 248K | 0 | 0 | 0 | 0 |
| Total Liabilities | 78.67M | 191.11M | 203.29M | 146.27M | 112.98M | 180.79M | 142.42M | 163.15M | 129.38M |
| Total Debt | 695K | 21.19M | 17.99M | 17.96M | 17.34M | 84.67M | 87.76M | 82.25M | 80.47M |
| Net Debt | -40.56M | -54.82M | -13.01M | -30.01M | -51.06M | -25.29M | -32.49M | -274.76M | -63.62M |
| Debt / Equity | - | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.23x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.18x |
| Interest Coverage | -1340.69x | -895.65x | -395.46x | -571.67x | -878.59x | -748.81x | -898.03x | -1250.50x | -2119.53x |
| Total Equity | -34.44M▲ 0% | -74.41M▼ 116.1% | 283.89M▲ 481.5% | 459.64M▲ 61.9% | 490.15M▲ 6.6% | 394.97M▼ 19.4% | 835.62M▲ 111.6% | 1.58B▲ 89.0% | 1.54B▲ 0% |
| Equity Growth % | - | -116.07% | 481.54% | 61.91% | 6.64% | -19.42% | 111.56% | 89.04% | 232.68% |
| Book Value per Share | -0.77 | -1.67 | 6.37 | 9.58 | 9.09 | 6.77 | 11.14 | 18.72 | 15.79 |
| Total Shareholders' Equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B | 1.54B |
| Common Stock | 0 | 0 | 4K | 5K | 6K | 6K | 7K | 8K | 8K |
| Retained Earnings | -35.21M | -76.46M | -128.76M | -228.98M | -383.79M | -530.75M | -754.61M | -1.07B | -1.14B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 6K | -128K | -660K | -4.95M | -552K | -1.49M | 1.8M | -4.19M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KYMR Cash Flow Statement
Kymera Therapeutics, Inc. (KYMR) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.86M | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M | -194.5M | -232.89M | -232.89M |
| Operating CF Margin % | - | 610.26% | 258.95% | -177.05% | -326.92% | -130.84% | -413.2% | -594.11% | - |
| Operating CF Growth % | - | 200.24% | 392.21% | -246.31% | -18.72% | 32.83% | -89.16% | -19.74% | -13.76% |
| Net Income | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.35M | -315.05M |
| Depreciation & Amortization | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | 8.29M |
| Stock-Based Compensation | 648K | 1.2M | 5.19M | 24.97M | 35.48M | 43.12M | 55.01M | 59.9M | 61.68M |
| Deferred Taxes | 0 | 0 | 1.57M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 443K | 54.34M | 332K | 5.83M | 889K | -11.8M | -9.06M | -5.02M | -43.16M |
| Working Capital Changes | 2.31M | 2.79M | 124.87M | -61.92M | -37.62M | 9.25M | -23.97M | 15.27M | 45.62M |
| Change in Receivables | -148K | 0 | -577K | 577K | -2.4M | -16.23M | 17.82M | 947K | 20M |
| Change in Inventory | 0 | 0 | 6.88M | 8.71M | 2.4M | 0 | 0 | 0 | 0 |
| Change in Payables | 824K | 0 | 990K | 54K | 253K | 0 | -307K | -1.97M | 3.2M |
| Cash from Investing | -1.36M | -16.49M | -422.59M | -99.83M | 20.52M | 139.89M | -404.08M | -521.06M | -712.52M |
| Capital Expenditures | -1.36M | -532K | -9.1M | -1.6M | -2.84M | -34.48M | -12.84M | -1.45M | -1.42M |
| CapEx % of Revenue | - | 18.13% | 26.73% | 2.19% | 6.06% | 43.87% | 27.27% | 3.7% | - |
| Acquisitions | 0 | 0 | 413.49M | 5.81M | -20.52M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -15.95M | -413.49M | -5.81M | 20.52M | 174.37M | 13.98M | 8.88M | -228.22M |
| Cash from Financing | 52.93M | 34.91M | 289.26M | 250.28M | 153M | 4.19M | 608.85M | 990.71M | 1.01B |
| Debt Issued (Net) | -295K | -371K | -554K | -849K | -1.13M | -76K | -1.58M | -1.49M | -1.22M |
| Equity Issued (Net) | 53.23M | 0 | 289.65M | 243.11M | 149.82M | 0 | 596.62M | 992.21M | 951.74M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 35.28M | 162K | 8.02M | 4.3M | 4.27M | 13.81M | 0 | 58.7M |
| Net Change in Cash | 33.71M▲ 0% | 36.33M▲ 7.8% | -45.2M▼ 224.4% | 21.5M▲ 147.6% | 20.43M▼ 5.0% | 41.25M▲ 101.9% | 10.27M▼ 75.1% | 236.76M▲ 2204.7% | 54.13M▲ 0% |
| Free Cash Flow | -19.22M▲ 0% | 17.37M▲ 190.4% | 79.03M▲ 354.9% | -130.54M▼ 265.2% | -155.92M▼ 19.4% | -137.31M▲ 11.9% | -207.34M▼ 51.0% | -234.34M▼ 13.0% | -244M▲ 0% |
| FCF Margin % | - | 592.13% | 232.22% | -179.24% | -332.98% | -174.71% | -440.47% | -597.81% | -474.1% |
| FCF Growth % | - | 190.39% | 354.92% | -265.17% | -19.44% | 11.94% | -51.01% | -13.02% | -1.68% |
| FCF per Share | -0.43 | 0.39 | 1.77 | -2.72 | -2.89 | -2.35 | -2.76 | -2.78 | -2.78 |
| FCF Conversion (FCF/Net Income) | 0.83x | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x | 0.75x | 0.77x |
| Interest Paid | 0 | 46K | 0 | 0 | 0 | 162K | 0 | 0 | 83K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KYMR Key Ratios
Kymera Therapeutics, Inc. (KYMR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -43.53% | -26.96% | -32.6% | -33.21% | -36.38% | -25.79% | -25.02% |
| Return on Invested Capital (ROIC) | - | -49.03% | -21.53% | -27.84% | -30.7% | -33.46% | -24.86% | -24.86% |
| Gross Margin | 71.88% | 100% | 100% | 100% | 100% | 100% | 100% | 33.23% |
| Net Margin | -1407.36% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.39% | -612.17% |
| Debt / Equity | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x | 0.05x | 0.05x |
| Interest Coverage | -895.65x | -395.46x | -571.67x | -878.59x | -748.81x | -898.03x | -1250.50x | -2119.53x |
| FCF Conversion | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x | 0.75x | 0.77x |
| Revenue Growth | - | 1059.99% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | -12.6% |
KYMR SEC Filings & Documents
Kymera Therapeutics, Inc. (KYMR) SEC filings — annual & quarterly reports (10-K, 10-Q)
KYMR Frequently Asked Questions
Kymera Therapeutics, Inc. (KYMR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kymera Therapeutics, Inc. (KYMR) reported $51.5M in revenue for fiscal year 2025.
Kymera Therapeutics, Inc. (KYMR) saw revenue decline by 16.7% over the past year.
Kymera Therapeutics, Inc. (KYMR) reported a net loss of $315.1M for fiscal year 2025.
Dividend & Returns
Kymera Therapeutics, Inc. (KYMR) has a return on equity (ROE) of -25.8%. Negative ROE indicates the company is unprofitable.
Kymera Therapeutics, Inc. (KYMR) had negative free cash flow of $244.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More KYMR
Kymera Therapeutics, Inc. (KYMR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates